EUVIMEDEUVIMED entdecken
Crossref

Incretin-based therapy for MASH: are two better than one?

Richard K. Sterling

Metabolism and Target Organ Damage · 17.06.2026 · 6 (2)

DOI: 10.20517/mtod.2026.74 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Metabolism and Target Organ Damage, online erschienen am 17.06.2026. Verfasst von Richard K. Sterling. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Sterling, R. K. (2026). Incretin-based therapy for MASH: are two better than one?. Metabolism and Target Organ Damage, 6(2). https://doi.org/10.20517/mtod.2026.74

Vancouver

Sterling RK. Incretin-based therapy for MASH: are two better than one?. Metabolism and Target Organ Damage. 2026;6(2). doi:10.20517/mtod.2026.74

BibTeX
@article{Sterling2026,
  author = {Sterling, Richard K.},
  title = {Incretin-based therapy for MASH: are two better than one?},
  journal = {Metabolism and Target Organ Damage},
  year = {2026},
  volume = {6},
  number = {2},
  doi = {10.20517/mtod.2026.74}
}
Kostenlos starten →